Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
3.23.2013
NICE to run VBP in the UK
Dear All,
now its out - NICE is broadening its role and will take on additional responsibilities as part of the VBP system in 2014.
Some links on the matter:
http://www.pharmafield.co.uk/Pf-Fox-News/NHS/2013/03/NICE-will-have-key-role-in-value-based-pricing
http://www.pmlive.com/pharma_news/nice_will_take_central_role_in_uks_value-based_pricing_system_468733
http://www.pharmatimes.com/Article/13-03-22/NICE_given_central_role_in_VBP_scheme.aspx
Cheers
Ulf
No comments:
Post a Comment